You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

Drugs with Dosage: AEROSOL


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Dosage: AEROSOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration Dosage
3m DUO-MEDIHALER isoproterenol hydrochloride; phenylephrine bitartrate AEROSOL, METERED;INHALATION 013296-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free AEROSOL, METERED;INHALATION
3m ISOPROTERENOL HYDROCHLORIDE isoproterenol hydrochloride AEROSOL, METERED;INHALATION 010375-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free AEROSOL, METERED;INHALATION
3m MEDIHALER ERGOTAMINE ergotamine tartrate AEROSOL, METERED;INHALATION 012102-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free AEROSOL, METERED;INHALATION
3m MEDIHALER-EPI epinephrine bitartrate AEROSOL, METERED;INHALATION 010374-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free AEROSOL, METERED;INHALATION
3m MEDIHALER-ISO isoproterenol sulfate AEROSOL, METERED;INHALATION 010375-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free AEROSOL, METERED;INHALATION
Allergan Herbert AEROSEB-DEX dexamethasone AEROSOL;TOPICAL 083296-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free AEROSOL;TOPICAL
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration >Dosage

Market Dynamics and Financial Trajectory for Pharmaceutical Drugs Dosed by Aerosol

Introduction

The pharmaceutical industry is witnessing significant growth in the segment of aerosol-based drug delivery systems. This growth is driven by several key factors, including the increasing prevalence of respiratory diseases, advancements in technology, and a shift towards more convenient and efficient treatment options.

Global Aerosol Market Overview

The global aerosol market, which includes pharmaceutical aerosols, was estimated at $83.29 billion in 2023 and is projected to grow at a CAGR of 6.9% from 2024 to 2030, reaching approximately $132.87 billion by 2030[1].

Pharmaceutical Aerosol Market Size and Growth

The global pharmaceutical aerosol market is a substantial segment within the broader aerosol market. In 2023, this market was valued at approximately USD 30 billion and is projected to reach around USD 50 billion by 2032, growing at a CAGR of 5.5%[1].

Key Drivers of Growth

Increasing Prevalence of Respiratory Diseases

The global increase in respiratory ailments such as asthma and chronic obstructive pulmonary disease (COPD) has significantly boosted the demand for aerosol-based pharmaceuticals. Metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are widely used for treating these conditions, providing immediate symptom alleviation by delivering medication directly to the lungs[3].

Technological Advancements

Advancements in propellant technology and formulations are crucial for the growth of the pharmaceutical aerosol market. The shift towards more eco-friendly alternatives like hydrofluoroolefins (HFOs) and compressed gases, despite the high upfront costs, is driven by stricter environmental regulations concerning volatile organic compounds (VOCs)[2].

Consumer Preferences and Convenience

Aerosol-based drug delivery systems offer precision and convenience, making them highly preferred by consumers. This is particularly evident in the personal care sector, where aerosol formats for products like deodorants, hair sprays, and shaving creams are gaining popularity[1].

Market Segmentation

Product Types

The market for inhalable drugs, which includes aerosol-based products, is segmented into aerosol, dry powder formulation, spray, and other product types. In 2023, dry powder formulation led with a market share of 38.4%, but aerosol formulations remain a significant segment due to their widespread use in MDIs and other respiratory treatments[3].

Indications

The market is primarily driven by respiratory diseases, which held a significant share of 62.1% in 2023. However, non-respiratory diseases also contribute to the demand for aerosol-based pharmaceuticals[3].

Distribution Channels

Hospital pharmacies dominate the distribution channel segment, holding the largest revenue share of 45.2% in the inhalable drugs market. Retail and online pharmacies also play important roles in the distribution of these products[3].

Regional Dynamics

North America

North America leads the inhalable drugs market with a revenue share of 48% in 2023, driven by advanced healthcare infrastructure, a high prevalence of respiratory diseases, and a robust regulatory environment conducive to pharmaceutical innovation[3].

Asia Pacific

The Asia Pacific region is expected to experience the highest CAGR during the forecast period due to rapid urbanization, increasing healthcare expenditure, and rising awareness about respiratory health issues. Governments in this region are prioritizing investments in healthcare infrastructure, which is expected to drive demand for inhalable drugs[3].

Financial Trajectory

Market Value

The global inhalable drugs market, which includes aerosol-based pharmaceuticals, generated a revenue of USD 32.4 billion in 2023 and is expected to reach USD 60.8 billion by 2033, growing at a CAGR of 6.5% during the forecast period[3].

Aerosol Propellants Market

The global aerosol propellants market, essential for pharmaceutical aerosols, is projected to reach USD 18.8 billion by 2033 from USD 10 billion in 2023, growing at a CAGR of 6.50% during the forecast period. Hydrocarbons currently hold an 80.2% share in this market due to their cost-effectiveness and broad compatibility[2].

Challenges and Opportunities

High Cost of Alternative Propellants

The transition to environmentally sustainable alternatives like HFOs and compressed gases imposes significant financial challenges. Developing and integrating these new propellants require substantial capital investment, which can deter smaller manufacturers and those in price-sensitive markets[2].

Specialized Applications

Exploring specialized applications for aerosol propellants beyond traditional markets offers a promising growth frontier. Emerging segments like the food industry and aerospace and defense sectors present lucrative opportunities for diversification and expansion[2].

Impact of Macroeconomic and Geopolitical Factors

Economic conditions such as GDP growth rates, inflation, and healthcare expenditure directly impact consumer purchasing power and healthcare budgets, influencing demand for pharmaceutical products. Geopolitical factors, including trade tensions and regulatory changes, can disrupt supply chains and increase manufacturing costs, affecting market growth[3].

Innovations and Sustainability

Innovations in propellant technology and formulations that reduce environmental impact without compromising product performance are key to capturing market share. The industry's shift towards more eco-friendly alternatives aligns with stricter environmental regulations and consumer preferences for sustainable products[2].

Key Takeaways

  • The global pharmaceutical aerosol market is projected to grow significantly, driven by the increasing prevalence of respiratory diseases and technological advancements.
  • Aerosol-based drug delivery systems offer precision and convenience, making them highly preferred by consumers.
  • The market is segmented by product types, indications, and distribution channels, with hospital pharmacies playing a dominant role.
  • North America and the Asia Pacific region are key markets, with the latter expected to experience the highest CAGR.
  • Financial challenges associated with transitioning to sustainable propellants and geopolitical factors can impact market growth.

FAQs

What is the projected growth rate of the global pharmaceutical aerosol market?

The global pharmaceutical aerosol market is projected to grow at a CAGR of 5.5% from 2023 to 2032[1].

Which region dominates the inhalable drugs market?

North America dominates the inhalable drugs market with a revenue share of 48% in 2023[3].

What are the key drivers of growth in the aerosol propellants market?

Key drivers include the increasing demand for personal care and pharmaceutical products, advancements in propellant technology, and a shift towards more eco-friendly alternatives[2].

How does the shift to sustainable propellants impact the market?

The shift to sustainable propellants like HFOs and compressed gases imposes significant financial challenges but aligns with stricter environmental regulations and consumer preferences for sustainable products[2].

What are the emerging segments for aerosol propellants beyond traditional markets?

Emerging segments include the food industry, aerospace, and defense sectors, which offer lucrative opportunities for diversification and expansion[2].

Sources

  1. Evergreen Resources: Aerosol Cans: Trends and Growth Insights for Brands.
  2. Market.US: Aerosol Propellants Market Size, Share, Growth - CAGR of 6.50%.
  3. Market.US: Inhalable Drugs Market Size, Share, Growth | CAGR of 6.5%.
  4. Grand View Research: U.S. Aerosol Market Size & Share | Industry Report, 2030.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.